• Users Online: 82
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2020  |  Volume : 8  |  Issue : 4  |  Page : 148-151

Renin–Angiotensin system implications to COVID-19 comorbidities


1 Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
2 Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Physiology, Faculty of Medicine, Cairo University, Cairo, Egypt

Correspondence Address:
Prof. Zienab Alrefaie
Department of Physiology, Faculty of Medicine, King Abdulaziz University and Department of Physiology, Faculty of Medicine, Cairo University, Cairo, Egypt

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jmau.jmau_105_20

Get Permissions

The role of the renin–angiotensin system (RAS) and its pharmacological modulators in the susceptibility and outcomes of SARS CoV-2 pandemic (COVID-19) has been much discussed recently. Angiotensin-converting enzyme type 2 (ACE2) has attracted much attention and debate in relevance to COVID-19. It not only acts as the receptor to which the SARS CoV-2 virus binds to be introduced into cells but also balances the effects of angiotensin II offering anti-inflammatory and antifibrotic protective actions to different organs. This mini-review aims to shed some light on the possible involvement of ACE2 and RAS alternate pathways in the comorbidities and clinical findings observed in COVID-19 patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed548    
    Printed30    
    Emailed0    
    PDF Downloaded78    
    Comments [Add]    

Recommend this journal